IBA signs contract with SteriLab for E-beam sterilization solution in the Dominican Republic
November 06 2024 - 1:00AM
UK Regulatory
IBA signs contract with SteriLab for E-beam sterilization solution
in the Dominican Republic
Fourth agreement secured by IBA Industrial
Solutions in past six weeks
Louvain-la-Neuve, Belgium, November 06,
2024 – IBA (Ion Beam Applications S.A), the world
leader in particle accelerator technology, has been selected by
SteriLab to equip its new facility at Haina Port in the Dominican
Republic with a cutting-edge Be Soft electron beam (E-beam)
sterilization solution. The facility will serve multiple sectors,
including medical devices, food products, and semiconductors,
helping manufacturers reduce logistics costs and improve
sterilization efficiency.
The Be Soft E-beam solution with lateral
irradiation for delicate products, which has been selected by
SteriLab, will be powered by IBA’s Rhodotron®
accelerator, and equipped with a conveyor, the Beagle production
line control system, a Building Safety System, and other advanced
components to ensure reliable, fast, and energy-efficient
sterilization. These features will allow SteriLab to meet the
demands of international standards while providing an
environmentally friendly alternative to traditional sterilization
methods like ethylene oxide.
This is the fourth consecutive agreement secured
by IBA’s Industrial Solutions team in the past six weeks. Alongside
the SteriLab contract, two further firm contracts have been signed,
and one binding term-sheet. They span both Europe and North
America, with IBA providing a range of integrated and standalone
E-beam and X-Ray solutions to its customers. Applications include
medical sterilization, material enhancement and food processing.
The typical price for each solution is EUR 10-15 million, depending
on configuration and options.
Thomas Servais, President of IBA
Industrial Solutions, commented: “We are thrilled to
work with SteriLab and to include them in the IBA Industrial User
Family as we begin this exciting partnership in the Dominican
Republic. We look forward to a long-term collaboration that will
benefit both of our companies and the communities we serve. The
four agreements we have concluded in quick succession underscore
the strength and range of the industrial solutions IBA offers, as
well as our ability to adapt to the growing market demand for both
E-beam and X-ray solutions.”
Franquiz Caraballo, Founder of SteriLab,
added: “After an extensive and strategic search, we
selected IBA as our supplier and strategic ally because of their
technology, their ability to deliver customized, scalable
solutions, and their commitment to innovation and sustainability.
Thanks to the E-beam solution, we will be able to provide our
clients with the highest quality and safest industrial
sterilization processes services as well as provide options to
current and future needs in Dominican Republic and the region. This
project aligns with our commitment to offer environmentally
friendly solutions that meet the exacting standards of the medical,
food, and semiconductor industries.”
Construction of the SteriLab facility is
expected to be completed by Q4 2025, with full operational
capability by Q4 2026. IBA will oversee the installation and
testing of the equipment, as well as training SteriLab’s team to
ensure compliance with international sterilisation standards.
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 2,000 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
CONTACTS
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
ICR Healthcare (Europe)
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
From Dec 2023 to Dec 2024